LipidBrick® is a novel range of proprietary cationic lipids dedicated to the formulation of LNPs for the development of mRNA-based vaccines and thera...
Meet our team at booth#64 during the World Vaccine Congress Europe 2023 in Barcelona, Spain on October 17th - 19th 2023. Don't miss the opportunity to check our poster presentation on: An innovative cationic lipid library for efficient and tunable mRNA-LNPs.
Poster : An innovative cationic lipid library for efficient and tunable mRNA-LNPs.
Lipid nanoparticles (LNP) have demonstrated high efficiency delivering RNA therapeutics in vivo. However, the properties of such nanoparticles obtained with conventional ionizable lipids are often hard to modulate, and especially their biodistribution profile. Such ionizable lipid-based nanoparticles often predominantly end up targeting the liver. One of the current challenges in the field consists of adjusting the particle chemical composition to the targeted application.
Here, we have characterized a library of 10 innovative imidazolium-based cationic lipids as key component of cationic LNPs (cLNP). We disclose their chemical structures and demonstrate their efficacy generating LNPs through characterization of their hydrodynamic diameters, Zeta potentials and encapsulation efficiencies. The resulting particles display high transfection efficiencies and have little to no impact on cell viability in vitro, on HEK293 and CaCo-2 cell lines. In vivo, the biodistribution of the cLNP highly depends on the cationic lipid chemical structures, targeting mainly lungs and spleen. Among this library, we have identified one cationic lipid as a potent additive in Moderna‘s Spikevax formulation. We improve the transfection efficiency of this formulation by 20% in vitro in HEK293 and Caco-2 cell lines and modulate its biodistribution profile in vivo.
- Tailored plasmid engineering
- Development and screening of different microbial expression systems
- Upstream and downstream process development including QC
- Production of R&D and GLP grade material at production scale ranging from 100 mg to 50g.
- Discover Polyplus’ wide range of transfection reagent for life science research and protein production at large scale.
Discover Our Applications
Cell & Gene Therapy
Success of Gene and Cell Therapies is dependent on efficient production of viral vectors that require optimized transfection reagents and viral vector engineering
RNA/DNA in vivo delivery is the most powerful alternative to viral vectors for nucleic acid-based therapies. They offer substantial advantages in terms of reliability,safety and costs for nucleic-acid based therapies
Broad range of solutions is needed for manufacturing of functional proteins or antibodies at the desired scale in bacteria, yeast and mammalian cell expression systems
Optimised plasmid engineering and specific transfection reagents are key to enable protein expression in a wide range of adherent and suspension mammalian cell types